Dr Zackon on the Use of Bispecific Antibodies in the Community Setting for R/R Myeloma

Ira Zackon, MD, discusses findings on the real-world utilization of bispecific antibodies in the treatment of relapsed/refractory multiple myeloma in the community oncology setting.

Ira Zackon, MD, hematologist, medical oncologist, New York Oncology Hematology; senior medical director, Ontada, discusses findings from a presentation at the 2024 ASH Annual Meeting on real-world bispecific antibody treatment in relapsed/refractory multiple myeloma in the community oncology setting.